AVA Bio Defender
Mutation-resistant Viral Defense Technologies
Company Overview
Snapshot
Founded in January 2007 by Lior Zigler, AVA Bio Defender operates with 1–10 employees. The company has raised $2.5 million across one funding round. AVA Bio Defender specializes in developing mutation-resistant viral defense technologies, currently with products in clinical trial.
Business overview
AVA Bio Defender is a biotechnology company focused on developing mutation-resistant viral defense technologies. The company utilizes siRNA and CRISPR technologies to create heritable genetic resistance in animals, specifically for poultry, and designs drugs for human therapy. Its core technology provides antiviral protection for all body cells and enables the development of medicines effective against viral mutations, serving the animal health and pharmaceutical markets globally.
Log in to access full profile ›Company Intelligence Q&A
- What is AVA Bio Defender's primary focus?
- AVA Bio Defender specializes in developing mutation-resistant viral defense technologies for both animal health and human therapy, utilizing advanced genetic engineering techniques.
- When was AVA Bio Defender founded?
- AVA Bio Defender was founded in January 2007.
- Who is the founder of AVA Bio Defender?
- Lior Zigler is the Founder and CEO of AVA Bio Defender.
- What technologies does AVA Bio Defender use?
- AVA Bio Defender employs siRNA technology for gene-delivery systems in animals and CRISPR technology for directed editing of target genomes. For human therapy, the company develops molecules to treat viral infections.
- What is AVA Bio Defender's current product stage?
- AVA Bio Defender's products are currently in the Clinical Trial stage, focusing on developing heritable genetic resistance in animals and drug design for human therapy.